Atara Biotherapeutics, Inc. (ATRA)
| Market Cap | 40.95M |
| Revenue (ttm) | 100.44M |
| Net Income (ttm) | -133.16M |
| Shares Out | 5.76M |
| EPS (ttm) | -22.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,397 |
| Open | 7.60 |
| Previous Close | 7.52 |
| Day's Range | 7.02 - 7.75 |
| 52-Week Range | 5.40 - 23.45 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 25.70 (+261.46%) |
| Earnings Date | Mar 27, 2025 |
About ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as we... [Read more]
Financial Performance
In 2023, Atara Biotherapeutics's revenue was $8.57 million, a decrease of -86.51% compared to the previous year's $63.57 million. Losses were -$276.13 million, 20.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is $25.7, which is an increase of 261.46% from the latest price.
News
The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bi...
The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bi...
The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bi...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the C...
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the C...
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bio...
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bio...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutic...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Co...
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.'s ATRA active Investigational New Drug (IND) applications.
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on ...
US FDA declines to approve Atara Biotherapeutics' cancer therapy
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically called tabelecleucel.